| Literature DB >> 34450238 |
Koyel Sen1, Tanu Mehta1, Sameera Sansare1, Leila Sharifi2, Anson W K Ma3, Bodhisattwa Chaudhuri4.
Abstract
Pharmaceutical applications of the 3D printing process have recently matured, followed by the FDA approval of Spritam, the first commercial 3D printed dosage form. Due to being a new technology in the conventional dosage formulation field, there is still a dearth of understanding in the 3D printing process regarding the effect of the raw materials on the printed dosage forms and the plausibility of using this technology in dosage development beyond the conventional ways. In this review, the powder-based binder jet 3D printing (BJ3DP) process and its pharmaceutical applications have been discussed, along with a perspective of the formulation development step. The recent applications of BJ3DP in pharmaceutical dosage development, the advantages, and limitations have further been discussed here. A discussion of the critical formulation parameters that need to be explored for the preformulation study of the solid oral dosage development using the BJ3DP process is also presented.Entities:
Keywords: 3D printing; Binder-jet; Pharmaceutical dosage form; Solid oral dosage form
Mesh:
Substances:
Year: 2021 PMID: 34450238 DOI: 10.1016/j.addr.2021.113943
Source DB: PubMed Journal: Adv Drug Deliv Rev ISSN: 0169-409X Impact factor: 15.470